Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Document Type
Year range
2.
Jundishapur Journal of Microbiology ; 15(8), 2022.
Article in English | Scopus | ID: covidwho-2080808

ABSTRACT

Background: Despite several challenges, the SARS-CoV-2 pandemic is still not over. Rapid mass-scale immunization is critical to prevent further COVID-19-associated deaths. Objectives: Herein, we aimed to evaluate the rapid ramp-up effects of spike antibodies in response to Sputnik V, Sinopharm, and SinoVac first dose administration in the general public of Pakistan. Methods: A cross-sectional study was conducted on 2000 participants to examine Sputnik V, Sinopharm, and SinoVac first dose effects 21 days post-administration. From 1200 real-time PCR negative subjects, the samples were subjected to SARS-CoV-2 spike antibody levels using electro-chemiluminescence immunoassay (ECLIA) (Elecsys, # 09289267190 Roche, USA). Results: SARS-CoV-2 spike protein positivity was detected highest at 87% among participants receiving SputnikV with SARS-CoV-2 spike protein antibodies > 1.5 AU/mL compared to 47.6% and 25% in individuals receiving Sinopharm and SinoVac, respectively. Also, 36.04% of the Sputnik-administered individuals depicted antibody levels > 250 AU/mL. Of the participants, 55% had a previous history of COVID-19. Also, 14.86%, 4.76%, and 0% of the SputnikV, Sinopharm, and SinoVac administered subjects showed antibodies > 100 AU/mL, respectively, while > 25 AU/mL antibodies were found in 10.70% of SputnikV, 19.04% of Sinopharm and 10.71% of SinoVac administered individuals. Moreover, > 1.5-2.5 AU/mL antibodies levels were found in 25.10%, 23.80%, and 14.28% of participants with SputnikV, Sinopharm, and SinoVac administered vaccines, respectively. The antibody titers of < 1.5 AU/mL were detected among 13.30%, 52.38%, and 46.42% of subjects administered with SputnikV, Sinopharm, and SinoVac vaccines, respectively. Conclusions: Even before administrating the second booster dose of SputnikV, a significantly higher number of patients depicted rapid ramp-up of SARS-CoV-2 specific spike antibodies, which can significantly contribute to rapid mass-immunization. Despite all challenges, persistent antibody plateau monitoring is critical to attaining humoral immunity against SARS-CoV-2 infections. © 2022, Author(s).

3.
Jundishapur Journal of Microbiology ; 14(6), 2021.
Article in English | EMBASE | ID: covidwho-1526966

ABSTRACT

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) preferentially infects respiratory tract cells, but it has organotropism. Middle East respiratory syndrome coronavirus (MERS-CoV) is significantly distinct from common cold and SARS coronavirus. In past few years, the SARS-CoV-2 and MERS-CoV caused several deaths in South Korea. The aim of current study was to assess SARS-CoV-2 and MERS-CoV awareness and epidemic prevention ability in South Koreans.According to our results, out of 1500 participants, 98.8% and 64.3% were aware of SARS-CoV-2 and MERS-CoV, respectively. Moreover, 97% of the participants used masks for prevention of airborne diseases, while 65.3% of the participants reused the same mask for several days. In addition, 50% of the participants were not satisfied with the government support. Future viral epidemics can be prevented by disseminating advanced knowledge and awareness among general public.

SELECTION OF CITATIONS
SEARCH DETAIL